CCR5 inhibitor maraviroc also blocks cell migration and metastasis, but not directly affects the angiogenesis pathway in triple negative breast cancer cell lines (Lee et al., 2014). The gene discussed is CCR5; the disease is triple-negative breast carcinoma.